DeepMed Research

Nemtabrutinib

Generic Name: Nemtabrutinib

Clinical Trials

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Phase 3

Recruiting

Conditions: CLL
Small-Cell Lymphoma
Lymphoma, Small Lymphocytic
SLL
Leukemia, Chronic Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Nemtabrutinib
Drug: Venetoclax
Biological: Rituximab

First Posted Date: 2023-07-17

Last Posted Date: 2025-05-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 720

Registration Number: NCT05947851

Locations: 🇺🇸
Memorial Hospital West ( Site 5410), Pembroke Pines, Florida, United States
🇺🇸
Oregon Health and Science University ( Site 5425), Portland, Oregon, United States
🇧🇷
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308), Sao Paulo, Brazil

and more 106 locations

A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

Phase 1

Active, not recruiting

Conditions: Mature B-cell Neoplasms

Interventions: Drug: Nemtabrutinib

First Posted Date: 2023-01-06

Last Posted Date: 2024-01-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 12

Registration Number: NCT05673460

Locations: 🇯🇵
National Cancer Center Hospital East ( Site 0002), Kashiwa, Chiba, Japan
🇯🇵
Kyushu University Hospital ( Site 0008), Fukuoka, Japan
🇯🇵
Chiba Cancer Center ( Site 0005), Chiba, Japan

and more 4 locations

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Nemtabrutinib
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine
Biological: Rituximab
Biological: Truxima
Biological: Ruxience
Biological: Riabni

First Posted Date: 2022-11-22

Last Posted Date: 2024-12-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT05624554

Locations: 🇺🇸
Highlands Oncology Group ( Site 5205), Springdale, Arkansas, United States
🇺🇸
Clermont Oncology Center ( Site 5224), Clermont, Florida, United States
🇺🇸
Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg, Mississippi, United States

and more 94 locations

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Phase 2

Recruiting

Conditions: Mantle Cell Lymphoma
Richter Transformation Lymphoma
Chronic Lymphocytic Leukemia
Follicular Lymphoma

Interventions: Biological: Zilovertamab vedotin
Drug: Nemtabrutinib

First Posted Date: 2022-07-14

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 223

Registration Number: NCT05458297

Locations: 🇪🇸
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( Site 4001), Salamanca, Spain
🇸🇪
Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan, Sweden
🇸🇪
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan, Sweden

and more 106 locations

A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

Phase 1

Active, not recruiting

Conditions: Hematological Malignancies

Interventions: Drug: Nemtabrutinib

First Posted Date: 2022-04-26

Last Posted Date: 2023-04-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 12

Registration Number: NCT05347225

Locations: 🇨🇳
Guangdong Provincial People's Hospital-hematology department ( Site 1002), Guangzhou, Guangdong, China
🇨🇳
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007), Guangzhou, Guangdong, China
🇨🇳
Henan Cancer Hospital-hematology department ( Site 1003), Zhengzhou, Henan, China

and more 2 locations

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Phase 2

Recruiting

Conditions: Non-Hodgkins Lymphoma
Hematologic Malignancies
Waldenstroms Macroglobulinaemia
Chronic Lymphocytic Leukaemia

Interventions: Drug: Nemtabrutinib

First Posted Date: 2021-01-28

Last Posted Date: 2025-05-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 490

Registration Number: NCT04728893

Locations: 🇮🇱
Rambam Medical Center ( Site 1301), Haifa, Israel
🇺🇸
Highlands Oncology Group ( Site 2728), Springdale, Arkansas, United States
🇺🇸
University of California San Diego Moores Cancer Center ( Site 2717), La Jolla, California, United States

and more 118 locations

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Waldenstrom Macroglobulinemia
Follicular Lymphoma
Lymphoma, B-Cell
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Richter's Transformation
Diffuse Large B Cell Lymphoma

Interventions: Drug: Nemtabrutinib

First Posted Date: 2017-05-22

Last Posted Date: 2024-11-11

Lead Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Target Recruit Count: 190

Registration Number: NCT03162536

Locations: 🇺🇸
UCLA Hematology & Oncology ( Site 0017), Los Angeles, California, United States
🇺🇸
Mayo Clinic Hospital ( Site 0140), Scottsdale, Arizona, United States
🇺🇸
University of Michigan ( Site 0018), Ann Arbor, Michigan, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy